Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. - Wikidata - wikimedia - TriplyDB

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

http://www.wikidata.org/entity/Q39085630

about

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Role of bone-anabolic agents in the treatment of breast cancer bone metastases Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Molecular pathways and targets in prostate cancer A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Development of cabozantinib for the treatment of prostate cancer.Managing bone metastases and reducing skeletal related events in prostate cancer.Current role of cabozantinib in metastatic castration-resistant prostate cancer.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.Modulation of cabozantinib efficacy by the prostate tumor microenvironment.BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts.

P2860

Q26741450-AE9E73E6-A86B-4FF9-A65A-AE1997F8331F Q26822732-E6A415C5-51A7-4B32-B336-DB6F6FE588E5 Q27011423-A83E489D-1E96-4A84-AA58-07F56A1A6CDA Q33769437-C6C3A321-6B28-4629-8D0A-6B5A7EB2023C Q33788066-49162176-F1F6-49E8-84F1-D7C87D6D9DE9 Q34330748-DA995E42-1F58-4670-BB31-F950710C5436 Q34365632-A6D88531-87B5-46D4-8A90-03D0DF7E0A98 Q34657338-5CA8BA6A-1617-4394-A1C2-08A488E5D1D7 Q34987693-E95646DD-5DE0-45E5-9E8B-631A712498F2 Q35985270-9FF75AF2-3CCA-4777-8D9A-A7C8141C8FE7 Q36436763-5348CA00-E860-442A-A8B0-A1C11C07ED5F Q36621024-2A769BDA-5A27-4E8D-93A6-CD1012798470 Q37527541-7B587572-EBF5-4C64-BD0F-3A06A2AA244E Q37665068-69877942-E233-4486-967F-1FCA7E2CA5E0 Q38208820-37EC02A3-59CD-4B19-9F4D-D9C12F657EB1 Q38211359-496FA4B5-2D5D-4BA0-B3BB-11482C7C9B2A Q38317384-92B72730-19EB-4296-86B8-136B63F5AC65 Q38430335-8B62A288-30A9-44AC-A4D8-FBD3B0CA4BC5 Q38700342-B020BCDF-E401-451F-B8D9-A1FBFF373C93 Q38723404-F4D042F4-8E1D-4C6C-97D9-6E2463A08D3C Q38735527-B5808CC7-76B6-45B9-9144-7263DBA0EFB2 Q38751138-A9BA6E22-7EB7-4F20-85BE-170335F307E8 Q38979283-A3386FA8-CA91-42FE-A23B-913A3E60B7AB Q42135817-7DF570D5-B913-4525-AD42-83A848E4EE79 Q44676922-CC8BECAC-140D-4057-A66A-BB611E0C9E57 Q46493299-9028F289-0BCB-4DD6-AD3A-EAD0A7F76D28 Q47129742-547E75C5-3B01-4473-AA1A-9CF9E733F505 Q48110513-B58B36C8-7979-40C9-A532-7D3EB0F65772 Q52665713-0CF3FD57-83B9-4836-84E9-6CB919C36A6C Q55474543-E77FEF8B-F70F-41C0-9A0A-25BBD27A6412

P2860

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

http://www.wikidata.org/entity/Q39085630

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@en

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@nl

type

label

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@en

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@nl

prefLabel

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@en

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@nl

P1433

Q39085630-8529571F-8DE3-4BF6-ACC5-C88915EEB6B0

P1476

Q39085630-57209DCA-73B5-4139-9B8F-7A4E95B2A87E

P2093

Q39085630-0B19ED18-AAD1-40C0-BEF5-33803EE671C1

Q39085630-1B7616D9-D9D9-4564-8F85-E144AC19EAFE

Q39085630-5A180166-0F63-41CA-8C75-24C09E3230DB

Q39085630-71913924-346B-43BC-9709-D76C520019D5

Q39085630-A28B5FCB-1722-4708-86B0-5DFA67461402

Q39085630-AA25F901-E11B-4161-933E-369EE43194EE

Q39085630-B1958053-C778-4B89-8E8D-8793512DD936

Q39085630-BC447321-ACBF-452D-AF7A-BFCEE0380FF9

P2860

Q39085630-05DB4913-F6FA-464D-9452-21B4BB81A0FB

Q39085630-0B487FCD-A973-4FA2-9407-9FF5F7834199

Q39085630-0FA08E43-CA2F-4CAB-9578-CD5343A7DEA2

Q39085630-11414977-08F3-48A4-AF1A-F73D081412FD

Q39085630-114687FC-C063-4D82-85A3-29CCB81A2DB7

Q39085630-14198A7A-B7E7-41FB-AE6F-B345E5FC0448

Q39085630-1705288F-C62D-4475-B731-7393F2449DBA

Q39085630-2510135D-B688-43DF-B81E-477DF5D940AE

Q39085630-269DB556-A16D-43A6-9891-D28C66017689

Q39085630-283E364D-2971-45ED-B839-4A2F8C370B61

P304

Q39085630-F318BD93-9AD3-4292-A727-F44A33BE9532

P31

Q39085630-F7FEDBAF-0207-4B53-80B8-77658A5FE2D7

P356

Q39085630-6F3DE67D-C1E4-445E-BDF5-A7A646745B48

P407

Q39085630-6AB19CC0-2C72-480D-9E45-ABCCE8D2E10F

P433

Q39085630-AD9D58A1-9E54-4481-A30C-84689D003DC9

P478

Q39085630-C51BC634-EA0F-4A8A-9BF9-745580F82822

P577

Q39085630-99BE2B37-914C-457F-8A91-2632F7AA2ABF

P698

Q39085630-590851C1-721A-4110-9B03-2A1908C3DEA1

P932

Q39085630-549D79A6-9FFC-4DA4-989F-27FF1713E852

P356

1078-0432.CCR-13-0839

P1433

Clinical Cancer Research

P1476

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

@en

P2093

Andreas Karatsinides

http://www.w3.org/2001/XMLSchema#string

Dana T Aftab

http://www.w3.org/2001/XMLSchema#string

Evan T Keller

http://www.w3.org/2001/XMLSchema#string

Frauke Schimmoller

http://www.w3.org/2001/XMLSchema#string

Honglai Zhang

http://www.w3.org/2001/XMLSchema#string

Jill M Keller

http://www.w3.org/2001/XMLSchema#string

Jinlu Dai

http://www.w3.org/2001/XMLSchema#string

Kenneth M Kozloff

http://www.w3.org/2001/XMLSchema#string

P2860

Prostate cancer and the met hepatocyte growth factor receptor

Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Efficacy of c-Met inhibitor for advanced prostate cancer.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Management of painful bone metastases.

The role of osteoclastic activity in prostate cancer skeletal metastases.

MET and VEGF: synergistic targets in castration-resistant prostate cancer

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

P304

617-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0839

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24097861

http://www.w3.org/2001/XMLSchema#string

P932

3946460

http://www.w3.org/2001/XMLSchema#string